STOCK TITAN

Gossamer Bio (NASDAQ: GOSS) awards 115K stock options to director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Gossamer Bio, Inc. director John D. Quisel received a grant of stock options covering 115,000 shares of common stock as board compensation. The options have an exercise price of $0.178 per share and expire on June 3, 2036.

The entire option grant becomes fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, conditioned on his continued board service. This is a routine non-employee director award rather than an open-market share purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Quisel John D
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 115,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 115,000 shares (Direct, null)
Footnotes (1)
  1. Award made pursuant to Non-Employee Director Compensation Program. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Option grant size 115,000 shares Stock option award to director John D. Quisel
Exercise price $0.178 per share Stock option exercise price
Expiration date June 3, 2036 Option expiration for 115,000-share grant
Shares underlying options 115,000 shares Common stock underlying granted options
Total derivative holdings after grant 115,000 options Total options held following this transaction
Non-Employee Director Compensation Program financial
"Award made pursuant to Non-Employee Director Compensation Program."
stock option financial
"The entire number of shares subject to this option becomes fully vested..."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"becomes fully vested and exercisable on the first to occur of (a) the first anniversary..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
grant date financial
"the first anniversary of the grant date or (b) the next occurring annual meeting..."
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
exercise price financial
"conversion_or_exercise_price": "0.1780""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Quisel John D

(Last)(First)(Middle)
3115 MERRYFIELD ROW, SUITE 120

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Gossamer Bio, Inc. [ GOSS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.17806/04/2026A115,000(1) (2)06/03/2036Common Stock115,000$0115,000D
Explanation of Responses:
1. Award made pursuant to Non-Employee Director Compensation Program.
2. The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Remarks:
/s/ Christian Waage, Attorney-in-Fact06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Gossamer Bio (GOSS) disclose in this Form 4 filing?

Gossamer Bio disclosed that director John D. Quisel received a stock option grant for 115,000 shares. The award is part of the company’s Non-Employee Director Compensation Program and represents routine equity-based board compensation rather than an open-market transaction.

How many Gossamer Bio (GOSS) options were granted to John D. Quisel?

John D. Quisel was granted options covering 115,000 shares of Gossamer Bio common stock. These options give him the right to buy shares at a fixed price, subject to vesting and expiration terms defined in the company’s director compensation program.

What is the exercise price of the Gossamer Bio (GOSS) options granted?

The stock options granted to John D. Quisel have an exercise price of $0.178 per share. This is the price he must pay per share to acquire Gossamer Bio common stock once the options have vested and before they expire, assuming he chooses to exercise.

When do John D. Quisel’s Gossamer Bio (GOSS) options vest?

All 115,000 options become fully vested and exercisable on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders. Vesting is conditioned on his continued service on Gossamer Bio’s board of directors through the applicable vesting date.

When do the Gossamer Bio (GOSS) options granted to John D. Quisel expire?

The options granted to John D. Quisel expire on June 3, 2036. He can exercise vested options any time before this expiration date, subject to the plan’s terms and his continued eligibility under Gossamer Bio’s Non-Employee Director Compensation Program.

Is this Gossamer Bio (GOSS) Form 4 a market buy or sell of shares?

No, this Form 4 reflects a grant of stock options as compensation, not a market purchase or sale of shares. The options were awarded under Gossamer Bio’s Non-Employee Director Compensation Program and do not involve immediate cash transactions in the open market.